SCHEMBL624938

SCHEMBL624938

NCCCCCCN(N)N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.55
DNM1 Q05193 9/20 0.53
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA3 P07451 2/20 0.53
CA4 P22748 2/20 0.53
CA6 P23280 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
BLM P54132 1/20 0.53
NFKB1 P19838 1/20 0.47
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18342693 1.00
Hydrochloric Acid SCHEMBL17102164 0.97 CHRM2 (0.52) CHRM2DNM1CA12CA1CA2
SCHEMBL18342675 0.97
SCHEMBL14738852 0.86 ALDH1A1 (0.38) CHRM2DNM1TSHRALDH1A1
SCHEMBL31240836 0.76 CHRM2 (0.58) CHRM2DNM1CA12CA1CA2
SCHEMBL1273916 0.76 CHRM2 (0.58) CHRM2DNM1CA12CA1CA2
SCHEMBL720253 0.76 CHRM2 (0.58) CHRM2DNM1CA12CA1CA2
SCHEMBL27297758 0.76 CHRM2 (0.58) CHRM2DNM1CA12CA1CA2
SCHEMBL8945918 0.73
SCHEMBL817873 0.73 CHRM2 (0.55) CHRM2DNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402482-B Bismaleic acid alcohol ester heat stabilizer with oxygen bridge molecular structure and preparation method thereof 江南大学 2024-06-25 CN claimed
EP-2650282-B1 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO (JP) 2017-06-07 EP claimed
EP-2650283-B1 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO (JP) 2017-06-07 EP claimed
US-9302274-B2 Collector compositions and methods of using the same CYTEC TECHNOLOGY CORP. (US) 2016-04-05 US claimed
US-9302272-B2 Froth flotation processes CYTEC TECHNOLOGY CORP. (US) 2016-04-05 US claimed
US-9000156-B2 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO., LTD. (JP) 2015-04-07 US claimed
EP-2141149-B1 PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE NIPPON SODA CO (JP) 2014-10-29 EP claimed
EP-2768618-A2 FROTH FLOTATION PROCESSES Cytec Technology Corp. (US) 2014-08-27 EP claimed
EP-2768616-A2 COLLECTOR COMPOSITIONS AND METHODS OF USING THE SAME Cytec Technology Corp. (US) 2014-08-27 EP claimed
EP-2650283-A1 Process for producing substituted methylamine compound and triazine derivative NIPPON SODA CO., LTD. (JP) 2013-10-16 EP claimed
WO-2013059259-A2 FROTH FLOTATION PROCESSES CYTEC TECHNOLOGY CORP. (US) 2013-04-25 WO claimed
US-20130092603-A1 Collector Compositions and Methods of Using the Same CYTEC TECHNOLOGY CORP. (US) 2013-04-18 US claimed
US-20130092604-A1 Froth Flotation Processes CYTEC TECHNOLOGY CORP. (US) 2013-04-18 US claimed
US-20100121054-A1 PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE NIPPON SODA CO., LTD. (JP) 2010-05-13 US claimed
EP-2141149-A1 PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE Nippon Soda Co., Ltd. (JP) 2010-01-06 EP claimed
US-5204482-A Ethylenediamine monoamide heteroaryl derivatives HOFFMAN-LAROCHE INC. (US) 1993-04-20 US claimed
EP-0330218-A2 Inhibitors of lysyl oxidase MERRELL DOW PHARMACEUTICALS INC. (US) 1989-08-30 EP claimed
EP-0067105-B1 ALLYL AMINE MAO INHIBITORS MERRELL DOW FRANCE ET CIE (FR) 1987-09-23 EP claimed
EP-0125684-B1 2-ALKYLTHIO-1-AMINOALKYL-2-PYRROLINE-3-CARBONITRILES, PROCESS FOR THEIR PREPARATION AND MEDICINES WITH ANTI-THROMBOTIC EFFECTS CONTAINING THEM GÖDECKE AKTIENGESELLSCHAFT (DE) 1987-07-08 EP claimed
EP-0067105-A2 Allyl amine MAO inhibitors MERRELL DOW FRANCE ET CIE (FR) 1982-12-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121054-A1 PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE INMT, BHMT2, HNMT CHRM2 107/4885DNM1 4200/4885CA12 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.